Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
10.1007/s10147-021-01869-0
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
SPRINGER JAPAN KK
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/218517 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
id |
sg-nus-scholar.10635-218517 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-2185172023-10-31T08:21:27Z Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations Chang, Gee-Chen Lam, David Chi-Leung Tsai, Chun-Ming Chen, Yuh-Min Shih, Jin-Yuan Aggarwal, Shyam Wang, Shuhang Kim, Sang-We Kim, Young-Chul Wahid, Ibrahim Li, Rubi Lim, Darren Wan-Teck Sriuranpong, Virote Chan, Raymond Tsz-Tong Lorence, Robert M Carriere, Philippe Raabe, Christina Cseh, Agnieszka Park, Keunchil DUKE-NUS MEDICAL SCHOOL Science & Technology Life Sciences & Biomedicine Oncology Afatinib HER2 mutations Lung cancer Named patient use NSCLC Uncommon EGFR mutations 10.1007/s10147-021-01869-0 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 26 5 841-850 2022-04-07T03:54:00Z 2022-04-07T03:54:00Z 2021-03-30 2022-04-07T02:15:30Z Article Chang, Gee-Chen, Lam, David Chi-Leung, Tsai, Chun-Ming, Chen, Yuh-Min, Shih, Jin-Yuan, Aggarwal, Shyam, Wang, Shuhang, Kim, Sang-We, Kim, Young-Chul, Wahid, Ibrahim, Li, Rubi, Lim, Darren Wan-Teck, Sriuranpong, Virote, Chan, Raymond Tsz-Tong, Lorence, Robert M, Carriere, Philippe, Raabe, Christina, Cseh, Agnieszka, Park, Keunchil (2021-03-30). Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 26 (5) : 841-850. ScholarBank@NUS Repository. https://doi.org/10.1007/s10147-021-01869-0 13419625 14377772 https://scholarbank.nus.edu.sg/handle/10635/218517 en SPRINGER JAPAN KK Elements |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
language |
English |
topic |
Science & Technology Life Sciences & Biomedicine Oncology Afatinib HER2 mutations Lung cancer Named patient use NSCLC Uncommon EGFR mutations |
spellingShingle |
Science & Technology Life Sciences & Biomedicine Oncology Afatinib HER2 mutations Lung cancer Named patient use NSCLC Uncommon EGFR mutations Chang, Gee-Chen Lam, David Chi-Leung Tsai, Chun-Ming Chen, Yuh-Min Shih, Jin-Yuan Aggarwal, Shyam Wang, Shuhang Kim, Sang-We Kim, Young-Chul Wahid, Ibrahim Li, Rubi Lim, Darren Wan-Teck Sriuranpong, Virote Chan, Raymond Tsz-Tong Lorence, Robert M Carriere, Philippe Raabe, Christina Cseh, Agnieszka Park, Keunchil Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
description |
10.1007/s10147-021-01869-0 |
author2 |
DUKE-NUS MEDICAL SCHOOL |
author_facet |
DUKE-NUS MEDICAL SCHOOL Chang, Gee-Chen Lam, David Chi-Leung Tsai, Chun-Ming Chen, Yuh-Min Shih, Jin-Yuan Aggarwal, Shyam Wang, Shuhang Kim, Sang-We Kim, Young-Chul Wahid, Ibrahim Li, Rubi Lim, Darren Wan-Teck Sriuranpong, Virote Chan, Raymond Tsz-Tong Lorence, Robert M Carriere, Philippe Raabe, Christina Cseh, Agnieszka Park, Keunchil |
format |
Article |
author |
Chang, Gee-Chen Lam, David Chi-Leung Tsai, Chun-Ming Chen, Yuh-Min Shih, Jin-Yuan Aggarwal, Shyam Wang, Shuhang Kim, Sang-We Kim, Young-Chul Wahid, Ibrahim Li, Rubi Lim, Darren Wan-Teck Sriuranpong, Virote Chan, Raymond Tsz-Tong Lorence, Robert M Carriere, Philippe Raabe, Christina Cseh, Agnieszka Park, Keunchil |
author_sort |
Chang, Gee-Chen |
title |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
title_short |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
title_full |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
title_fullStr |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
title_full_unstemmed |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations |
title_sort |
experience from asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon egfr mutations |
publisher |
SPRINGER JAPAN KK |
publishDate |
2022 |
url |
https://scholarbank.nus.edu.sg/handle/10635/218517 |
_version_ |
1781793039687090176 |